Evidence map›Paper›PMID 39995350›Full record

ArticleFuture medicinal chemistry2025

Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and

Reda R Mabrouk, Hazem A Mahdy, Abdallah E Abdallah, Ismail Celik, Abdelsalam Mohamed Abdelsalam Ouf, Mariam K Alamoudi, Aisha Alnami, Maged Mohammed Saleh Al Ward, Ahmed B M Mehany, Mohamed Ayman El-Zahabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Recent progress in the exploitation of anti-cancer small molecules targeting angiogenesis.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  2. Synthesis, antiproliferative evaluation andFuture medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Reda R MabroukPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Hazem A MahdyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Abdallah E AbdallahPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Ismail CelikPharmaceutical Chemistry Department, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
Abdelsalam Mohamed Abdelsalam OufPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Assiut, Egypt.
Mariam K AlamoudiDepartment of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Aisha AlnamiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Maged Mohammed Saleh Al WardPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Ahmed B M MehanyZoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo, Egypt.
Mohamed Ayman El-ZahabiPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew triazoloquinazoline derivatives were synthesized to explore their cytotoxic activity on various cancer cell lines, prompted by the need for effective anticancer agents. RESEARCH DESIGN AND

methodsAll synthesized compounds were confirmed by spectroscopic methods and tested in vitro for their inhibitory activities against hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and prostate cancer (PC3) cell lines. Ten compounds were tested

resultsCompounds

conclusionsCompound

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolinesTriazolesVascular Endothelial Growth Factor Receptor-2ApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsKDR protein, humanProtein Kinase InhibitorsQuinazolinesTriazolesVascular Endothelial Growth Factor Receptor-2ADMETangiogenesisbreast cancerMCF7PiperazineTriazoloquinazolineVEGFR2

Identifiers

PMID39995350
PMCPMC11901504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.